Trial Title:
Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC
NCT ID:
NCT05970705
Condition:
Metastatic Colorectal Cancer
Conditions: Official terms:
Colorectal Neoplasms
Trifluridine
Conditions: Keywords:
metastatic colorectal cancer
regorafenib
TAS-102
Trifluridine/Tipiracil
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Intervention model description:
controlled, randomized
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Regorafenib
Description:
this anti-angiogenesis targeting drug is one of the standard third-line treatment options
for patients with metastatic colorectal cancer
Arm group label:
A: Regorafenib+TAS-102 combination therapy
Arm group label:
B：Regorafenib monotherapy
Other name:
Stivaga
Intervention type:
Drug
Intervention name:
Trifluridine/Tipiracil
Description:
this chemotherapeutic drug is also one of the standard third-line treatment options for
patients with metastatic colorectal cancer
Arm group label:
A: Regorafenib+TAS-102 combination therapy
Other name:
TAS-102
Summary:
The purpose of this study is to evaluate the clinical benefit of regorafenib combined
with TAS-102 compared with regorafenib monotherapy in patients with metastatic colorectal
cancer who have failed at least two lines of treatment, to explore the rationality of
this combination therapy strategy and to obtain relevant survival and safety data.
Detailed description:
Based on the current diagnostic and treatment guidelines, regorafenib and TAS-102
monotherapy are both standard third-line treatment options for patients with metastatic
colorectal cancer (mCRC), yet the overall treatment sequence or preference is not clear.
A retrospective study directly compared the efficacy of regorafenib and TAS-102
monotherapy for third-line treatment of mCRC, and found similar efficacy between the two
treatments. However, the benefits of current third-line monotherapy for mCRC are still
limited. Patients who receive oral regorafenib monotherapy have an ORR of less than 5%,
disease control rate of 50-60%, and TAS-102 has an ORR of 1.1%-1.6% and a disease control
rate of less than 50% in third-line treatment of mCRC. These drugs have limited
prolongation of progression-free survival (PFS), and disease progression and drug
resistance often occur shortly after medication use. Most mCRC patients have a high tumor
burden during third-line treatment, and how to improve the remission rate of treatment,
improve patients' quality of life due to high tumor burden, increase disease control, and
further bring better survival benefits is still a big challenge for third-line treatment.
Regorafenib and TAS-102 have different mechanisms of action and different adverse
reaction spectra. When the two drugs are used in combination, they may complement each
other in terms of efficacy and are also less likely to have toxic effects.
In the RECOURSE study, 17% of patients in the TAS-102 treatment group had received prior
treatment with regorafenib. Subgroup analysis showed that the efficacy of TAS-102 was not
dependent on whether or not the patient had previously received regorafenib treatment.
Therefore, the combination of regorafenib and TAS-102 may be a valuable treatment option
for refractory mCRC. However, there is little clinical research data on whether the
combination therapy could further improve efficacy and prolong patient survival compared
to monotherapy. In 2021, a phase Ib small-sample study from Germany explored the combined
use of regorafenib and TAS-102 in third-line treatment of mCRC. The study included 12
patients who received combined treatment with regorafenib and TAS-102 in third-line
treatment. After a 3+3 dose-exploration trial, three cases of DLT were all grade 3
hypertension related to regorafenib. The combination of TAS-102 25 mg/m2 twice daily and
regorafenib 120 mg was well tolerated, with a median PFS of 3.81 months (95% CI:
1.51-5.2), and a median OS of 11.1 months (95% CI: 2.3-18.2). The results of this
early-phase clinical trial suggest that compared to regorafenib monotherapy in the
CORRECT study with a median PFS of less than two months and a median OS of less than
seven months, the third-line combination treatment of regorafenib and TAS-102 may
potentially provide patients with greater clinical benefits. In conclusion, the
combination therapy of regorafenib and TAS-102 may be further explored and studied for
late-stage colorectal cancer in third-line or after third-line treatment.
The aim of this study is to evaluate the clinical benefits and safety of the combination
of regorafenib and TAS-102 compared to regorafenib monotherapy in patients with advanced
colorectal cancer who have failed second-line or later treatments. The efficacy and
safety of the combination therapy will be fully evaluated, and explorations of efficacy,
PFS, OS, safety, and related biomarkers associated with the combined treatment of
regorafenib and TAS-102 will be conducted.
Criteria for eligibility:
Criteria:
A total of 101 patients with metastatic colorectal cancer who meet the inclusion criteria
and do not meet the exclusion criteria for receiving third-line or later-line therapy
will be randomly assigned to receive corresponding treatment in a 1:1 ratio.
Inclusion Criteria:
The subjects must meet all of the following criteria to be eligible for this study:
1. Patients with histologically confirmed recurrent/metastatic colorectal
adenocarcinoma.
2. Patients who have failed at least one prior standard first- or second-line therapy,
including fluoropyrimidine-based therapy, oxaliplatin, irinotecan, and bevacizumab.
Treatment failure is defined as either radiographic evidence of disease progression
or unacceptable toxicity during treatment or within three months following
completion of therapy.
(Note: a. each line of therapy should include at least one or more chemotherapy
agents administered for at least one cycle; b. adjuvant/neoadjuvant therapy is
allowed. If relapse or metastasis occurs during or within six months after
completion of adjuvant/neoadjuvant therapy, it is considered a failure of first-line
chemotherapy for progressive disease. c. For patients with RAS/RAF wild-type tumors,
the use of an EGFR inhibitor is not required.)
3. At least one measurable lesion, with the longest diameter ≥10 mm on spiral CT or ≥20
mm on conventional CT (RECIST 1.1 criteria).
4. ECOG performance status of 0-2.
5. Life expectancy of ≥12 weeks.
6. Adequate bone marrow, hepatic, and renal function measured within the screening
period prior to randomization: absolute neutrophil count (ANC) ≥1.5 × 109 /L,
hemoglobin ≥ 8.0 g/dL, platelet count ≥ 75 × 109 /L, total bilirubin <1.5 × ULN, ALT
and AST <2.5 × ULN (≤5 × ULN for patients with liver involvement), serum creatinine
≤1.5 × ULN, and creatinine clearance ≥50 mL/min.
7. Women of childbearing potential must use effective contraception.
8. Voluntarily participating in this study, signing the informed consent form,
understanding the purpose of the study and the necessary procedures, and willing to
participate in this study.
Exclusion Criteria:
Patients who meet any of the following criteria will be excluded from the study:
1. Proteinuria ≥2+ on dipstick or 24-hour urinary protein ≥1.0 g/24 h.
2. Abnormal coagulation function (PT>16s, APTT>43s, TT>21s, Fbg<2g/L), bleeding
tendency, or receiving thrombolysis or anticoagulation therapy.
3. Patients at risk of gastrointestinal bleeding, including those with active digestive
ulcers and fecal occult blood (++) and those with histories of black stools or
hematemesis within three months.
4. Receiving systemic antitumor therapy, including chemotherapy, signal transduction
inhibitors, or immune therapies, within three weeks prior to screening.
5. Patients with uncontrolled hypertension (systolic blood pressure >140 mmHg,
diastolic blood pressure >90 mmHg) despite antihypertensive medication, grade I or
higher coronary heart disease, grade I or higher arrhythmia (including QTc interval
prolongation with ≥450 ms for men and ≥470 ms for women), or grade I or higher heart
failure.
6. Patients with a history of thrombotic or embolic events requiring treatment within
the preceding six months.
7. Patients who have received radiation therapy targeting the selected target lesion.
8. Symptomatic brain or meningeal metastasis.
9. Uncontrolled pleural or peritoneal effusion.
10. Receiving kidney dialysis.
11. Serious or uncontrolled infection.
12. Pregnant or lactating women or women of childbearing potential without adequate
contraception.
13. Multiple factors affecting oral drug administration (dysphagia, chronic diarrhea,
and bowel obstruction).
14. Patients who have been treated with small molecule tyrosine kinase inhibitors
containing VEGFR (such as apatinib, fruquintinib, anlotinib, and lenvatinib).
15. Patients who have been treated with TAS-102.
16. Participation in another clinical study within four weeks prior to screening.
17. Patients with comorbidities that could seriously endanger patients' safety or affect
their completion of the study.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Fudan University Shanghai Cancer Center
Address:
City:
Shanghai
Zip:
200032
Country:
China
Status:
Recruiting
Contact:
Last name:
Chenchen Wang, M.D
Phone:
862154561523
Email:
wccnancy2003@aliyun.com
Investigator:
Last name:
Weijian Guo, M.D
Email:
Principal Investigator
Investigator:
Last name:
Chenchen Wang, M.D
Email:
Sub-Investigator
Start date:
July 1, 2023
Completion date:
July 4, 2026
Lead sponsor:
Agency:
Fudan University
Agency class:
Other
Source:
Fudan University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05970705
